Skip links
Orsini a specialty pharmacy partner for YORVIPATH® (palopegteriparatide), for hypoparathyroidism. Learn more →
Orsini now distributing BridgeBio's ATTRUBY™ (acoramidis), for ATTR-CM. Learn more →
Prescribe a Therapy
Orsini

← Back to Centers of Excellence

Endocrinology Center of Excellence

Supporting patients living with a rare endocrinology condition

Orsini’s Endocrinology Center of Excellence launched in 2015 with our first pediatric growth hormone program. Today we support multiple endocrinology programs across several rare conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Endocrinology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Home Health Nursing

Access nationwide nursing support for in-home treatment or self-administration training. Our nurses provide clinical support to help patients achieve their treatment goals.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Endocrinology Conditions Supported

Explore the rare endocrinology conditions and therapies Orsini supports below.

About Cushing’s Syndrome

Cushing’s syndrome, also known as hypercortisolism, is a rare condition that occurs when the body produces too much of the hormone cortisol. This can lead to bone loss, weight gain, high blood pressure, high blood sugar, and increased thirst, among other symptoms.

Cushing’s Syndrome Therapies Supported

 

Full Name Mifepristone
Drug Mifepristone
Manufacturer Generic
Route of Administration Oral
Site of Care Home
Approved Indication Control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery
Disease Cushing's Syndrome
Therapeutic Area Endocrinology
Enrollment Form Link Mifepristone Enrollment Form
Phone Number (888) 204-7730
Fax Number (877) 218-6288
Product Website https://www.tevausa.com/products/mifepristonetablets

About Hypoparathyroidism

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production or action of parathyroid hormone (PTH), a key regulator of calcium, phosphorus, and vitamin D metabolism. The condition leads to low calcium levels and elevated phosphorus levels in the blood and causes muscle aches and spasms. It may also cause kidney complications, cognitive impairment, and cardiac arrhythmias.

Hypoparathyroidism Therapies Supported

Full Name YORVIPATH® (palopegteriparatide)
Drug Yorvipath
Manufacturer Ascendis Pharma
Route of Administration Subcutaneous
Site of Care Home
Approved Indication The treatment of hypoparathyroidism in adults
Disease Hypoparathyroidism
Therapeutic Area Endocrinology
Enrollment Form Link Enrollment Form
Phone Number 888-204-7802
Fax Number 877-471-8175
Product Website yorvipathhcp.com

About Tumor-induced Osteomalacia (TIO)

Tumor-induced osteomalacia is a rare paraneoplastic syndrome characterized by weakened bones due to phosphate wasting. Tumors produce a hormone-like substance causing renal phosphate loss, leading to bone softening, fractures, and muscle weakness. Diagnosis involves identifying the tumor through imaging and blood tests.

TIO Therapies Supported

Full Name Crysvita® (burosumab-twza)
Drug Crysvita
Manufacturer Kyowa Kirin North America
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older
Disease Tumor-induced Osteomalacia (TIO); X-linked Hypophosphatemia (XLH)
Therapeutic Area Endocrinology & Bone Specialty
Enrollment Form Link Enrollment Form
Phone Number 800-240-7614
Fax Number 877-793-4897
Product Website crysvitahcp.com

About Type 1 Diabetes (T1D)

Type 1 diabetes is a chronic condition where the immune system mistakenly attacks and destroys insulin-producing cells in the pancreas. This results in insufficient insulin, leading to high blood sugar levels. Symptoms include increased thirst, frequent urination, and weight loss.

T1D Therapies Supported

Full Name Tzield® (teplizumab-mzwv)
Drug Tzield
Manufacturer Sanofi
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D
Disease Type 1 Diabetes (T1D)
Therapeutic Area Endocrinology & Bone Specialty
Enrollment Form Link Tzield Enrollment Form
Phone Number 800-670-5321
Fax Number 877-655-4364
Product Website tzield.com

About X-linked Hypophosphatemia (XLH)

X-linked hypophosphatemia is a genetic disorder causing low levels of phosphate in the blood. It results from mutations in the PHEX gene, affecting phosphate reabsorption in the kidneys. XLH leads to weakened bones, bowed legs, and dental issues.

XLH Therapies Supported

Full Name Crysvita® (burosumab-twza)
Drug Crysvita
Manufacturer Kyowa Kirin North America
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older
Disease Tumor-induced Osteomalacia (TIO); X-linked Hypophosphatemia (XLH)
Therapeutic Area Endocrinology & Bone Specialty
Enrollment Form Link Enrollment Form
Phone Number 800-240-7614
Fax Number 877-793-4897
Product Website crysvitahcp.com